Randomized Trialhigh evidence
Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial.
Addiction (Abingdon, England)·February 20, 2026·PMID 41720599
Why it mattersIt provides evidence that a pre-treatment neuroaffective biomarker can guide personalized smoking cessation pharmacotherapy, potentially improving outcomes by matching patients to the more effective medication.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled